Sponsor content

Novel immunotherapies to combine with PD-1/PD-L1 treatment

ImmuneOncia Therapeutics is developing antibodies that target novel immune checkpoints, which could enhance drug efficacy when used in combination with agents that block PD-1 or PD-L1.

Like 0 Comment
Page of
Go to the profile of ImmuneOncia Therapeutics Inc.

ImmuneOncia Therapeutics Inc.

ImmuneOncia was established as a joint venture between Sorrento Therapeutics, USA and Yuhan Corporation, Korea, focusing on immuno-oncology and aims to bring safe, effective immunotherapies to patients worldwide.

No comments yet.